<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04390776</url>
  </required_header>
  <id_info>
    <org_study_id>B7981029</org_study_id>
    <nct_id>NCT04390776</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of PF-06651600 Capsules Relative to Tablets and Estimation of Food Effect on Capsules.</brief_title>
  <official_title>A PHASE 1, RANDOMIZED, OPEN-LABEL, CROSS-OVER, SINGLE-DOSE STUDY TO EVALUATE THE BIOEQUIVALENCE OF CANDIDATE CAPSULE FORMULATIONS OF PF-06651600 TO TABLETS AND ESTIMATE THE EFFECT OF HIGH-FAT MEAL ON BIOAVAILABILITY IN HEALTHY PARTICIPANTS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will be conducted as a Phase 1, open-label, single-dose, randomized, 2- or 3&#xD;
      period, cross over design in a single cohort.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 28, 2020</start_date>
  <completion_date type="Actual">July 19, 2021</completion_date>
  <primary_completion_date type="Actual">July 19, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration-time profile from time zero extrapolated to infinite time (AUCinf)of PF-06651600</measure>
    <time_frame>Day 1 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 16 hrs, and Day 2, at 24 hours post-dose.</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum plasma PF-06651600 concentration (C max)</measure>
    <time_frame>Day 1 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 16 hrs, and Day 2, at 24 hours post-dose.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Single dose time to reach maximum observed plasma concentration (Tmax) of PF-06651600</measure>
    <time_frame>Day 1 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 16 hrs, and Day 2, at 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Area under the Curve from Time Zero to Last quantifiable concentration [AUC last) of PF-06651600</measure>
    <time_frame>Day 1 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 16 hrs, and Day 2, at 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose plasma decay half-life (t 1/2) of PF-06651600</measure>
    <time_frame>Day 1 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 16 hrs, and Day 2, at 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Apparent Oral Clearance (CL/F) of PF-06651600</measure>
    <time_frame>Day 1 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 16 hrs, and Day 2, at 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Single dose Apparent Volume of Distribution (Vz/F) of PF-06651600</measure>
    <time_frame>Day 1 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 12, and 16 hrs, and Day 2, at 24 hours post-dose.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of abnormal safety laboratory tests</measure>
    <time_frame>Baseline up to day 9</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of Adverse Events</measure>
    <time_frame>Baseline up to day 35</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">164</enrollment>
  <condition>Healthy Participants</condition>
  <arm_group>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2), and followed by Capsules (fed, Period 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2), and followed by Capsules (fed, Period 3).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06651600 100 mg Tablets (fasted, Period 1), followed by Capsules (fasted, Period 2).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PF-06651600 100 mg Capsules (fasted, Period 1), followed by Tablets (fasted, Period 2).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06651600</intervention_name>
    <description>PF-06651600 100 milligrams (mg) will be provided as Tablets and Capsules.</description>
    <arm_group_label>Treatment Sequence 1</arm_group_label>
    <arm_group_label>Treatment Sequence 2</arm_group_label>
    <arm_group_label>Treatment Sequence 3</arm_group_label>
    <arm_group_label>Treatment Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and female participants who are healthy as determined by medical evaluation&#xD;
             including a detailed medical history, complete physical examination, which includes BP&#xD;
             and pulse rate measurement, clinical laboratory tests, and cardiac evaluation&#xD;
             (including ECG).&#xD;
&#xD;
          -  BMI of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110 lb).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence or history of clinically significant hematological, renal, endocrine&#xD;
             (including diabetes), pulmonary, gastrointestinal, cardiovascular (including&#xD;
             hypertension and congestive heart failure), hepatic, psychiatric, neurological,&#xD;
             dermatological, or allergic disease (including drug allergies, but excluding&#xD;
             untreated, asymptomatic, seasonal allergies at the time of dosing).&#xD;
&#xD;
          -  Any condition possibly affecting drug absorption (eg, gastrectomy, cholecystectomy).&#xD;
&#xD;
          -  Known immunodeficiency disorder, including positive serology for human&#xD;
             immunodeficiency virus (HIV) at screening, or a first degree relative with a&#xD;
             hereditary immunodeficiency.&#xD;
&#xD;
        Participants with any of the following acute or chronic infections or infection history:&#xD;
&#xD;
          -  Any infection requiring treatment within 2 weeks prior to the dosing visit.&#xD;
&#xD;
          -  Any infection requiring hospitalization or parenteral antimicrobial therapy within 60&#xD;
             days of the first dose of study intervention.&#xD;
&#xD;
          -  Any infection judged to be an opportunistic infection or clinically significant by the&#xD;
             investigator, within the past 6 months of the first dose of study intervention.&#xD;
&#xD;
          -  Known active or history of recurrent bacterial, viral, fungal, mycobacterial or other&#xD;
             infections.&#xD;
&#xD;
          -  History of recurrent (more than one episode of) localized dermatomal herpes zoster, or&#xD;
             history of disseminated (single episode) herpes simplex or disseminated herpes zoster.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Centers of America ( Hollywood )</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33024</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prism Research LLC dba Nucleus Network</name>
      <address>
        <city>Saint Paul</city>
        <state>Minnesota</state>
        <zip>55114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://pmiform.com/clinical-trial-info-request?StudyID=B7981029</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2020</study_first_posted>
  <last_update_submitted>August 2, 2021</last_update_submitted>
  <last_update_submitted_qc>August 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

